CD8A and neoplasm: In preclinical models, we evaluated TCR clonality in peripheral CX3CR1+ CD8+ T cells only in highly-mutated MC38 tumor-bearing mice treated with combined anti-CTLA-4/PD-L1 blockade therapy.